drugset / Trial / NCT05765604
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)
RandomizedParallel-groupDouble-blindPrevention
Summary
Subjects aged 18 and above who have been completed primary or booster vaccination of COVID-19 inactivated vaccines for 3 months or more, to conduct a randomized, parallel controlled, double-blind, single-center phase I clinical trial of Recombinant variant COVID-19 vaccine (Sf9 cell)(WSK-V102) to evaluate the safety, tolerance and immunogenicity of this vaccine in the study population.
Timeline
- Start
- 2023-03-14
- Primary completion
- 2023-07-30
- Completion
- 2024-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Recombinant COVID-19 vaccine(CHO cell) | Vaccine | — | — |
| Subject | WSK-V102 | Unknown | — | — |